[Media Releases] Four public biotechs are jumping in super antibiotic for superbugs (Hankyung, 2 Sep 2014)
Title: Four public biotechs are jumping in super antibiotic for superbugs Publication: Hankuk Economy (Hankyung) / Min-Soo Han Date: 2 Sep 2014 URL: link to website (contents in Korean)
· Antibiotics has been one of LegoChem’s core therapeutic areas since inception. LegoChem has been developing three super antibiotics up until today. · The most advanced antibiotics is Oxazolidinone antiobiotics (LCB01-0371) for the treatment of respiratory tract and skin infection caused by gram-positive, drug-resistant super bacteria including MRSA and VRE. · LCB01-0371 shows excellent safety profile against mylosuppression, prompting longer treatment duration. · Next-generation Oxazolidinone antibiotics (LCB01-0699) is the first-in-class with broad spectrum against linezolid-resistant bacteria and some gram-negative bacteria. It is under preclinical in collaboration with Medicilon/Longthera in China. · Cephalosporin antibiotics (LCB10-0200), which is in preclinical in the UK, is against various gram-negative bacillus including P. aeruginosa, K. pneumonia, and A. baumanni. · According to an analyst from KDB Daewoo Securities, preclinical results will likely be reflected in clinical trials because antibiotics only kill bacterial cells unlike other drugs that can influence the human metabolic system.
About LegoChem Biosciences LegoChem Biosciences, Inc. (LCB) is a research-based biotechnology company dedicated to discovering, developing, and commercializing innovative medicines by leveraging our chemistry expertise to make conventional biologics targeted and more potent for the benefit of patients with diseases of high unmet medical needs. We are advancing sustainable pipelines in therapeutic areas in antibiotics, anti-coagulants, oncology, antibody-drug conjugate (ADC), and protein-drug conjugate (PDC). |